3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
35
Recruiting
26
Terminated
16
Active not recruiting
14
Withdrawn
8
Unknown
5
Suspended
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
1
Interventions
Carboplatin
126
Cisplatin
125
Drug Therapy
103
Bevacizumab
98
Oxaliplatin
97
Capecitabine
97
Radiotherapy
94
Gemcitabine
87
Paclitaxel
85
tislelizumab
84
Cyclophosphamide
82
pembrolizumab
77
Specimen Handling
77
toripalimab
69
Injections
63
Fluorouracil
62
Magnetic Resonance Spectroscopy
61
sintilimab
57
anlotinib
53
130-nm albumin-bound paclitaxel
51
Surgical Procedures, Operative
50
Docetaxel
49
fludarabine
46
Pemetrexed
45
venetoclax
42
Standard of Care
42
Leucovorin
42
Irinotecan
41
lenvatinib
40
Biopsy
39
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Interventional
×
talazoparib
×
Clear all
NCT05319249
2024-04-05
NAKIP-AML
German Cancer Research Center
Phase 1/2
Not yet recruiting
54 enrolled